BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20919747)

  • 1. Key features for designing phosphodiesterase-5 inhibitors.
    Chang TT; Huang HJ; Lee KJ; Yu HW; Chen HY; Tsai FJ; Sun MF; Chen CY
    J Biomol Struct Dyn; 2010 Dec; 28(3):309-21. PubMed ID: 20919747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
    Chen CY
    J Biomol Struct Dyn; 2010 Apr; 27(5):627-40. PubMed ID: 20085380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
    Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
    J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
    Yang GF; Lu HT; Xiong Y; Zhan CG
    Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
    Zhang H; Li H; Ma Q
    J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5.
    Chen CY
    J Mol Graph Model; 2009 Oct; 28(3):261-9. PubMed ID: 19747866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational insights into the inhibition of inosine 5'-monophosphate dehydrogenase by mycophenolic acid analogs: three-dimensional quantitative structure-activity relationship and molecular docking studies.
    Yang N; Wang J; Wang ZW; Wang QH; Yang HG; Wang XJ; Cheng MS
    Chem Biol Drug Des; 2012 Jun; 79(6):1063-71. PubMed ID: 22405057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
    Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
    Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
    Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
    Antunes JE; Freitas MP; da Cunha EF; Ramalho TC; Rittner R
    Bioorg Med Chem; 2008 Aug; 16(16):7599-606. PubMed ID: 18656371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.